Integrated imaging and treatment in one incubator workflow for photodynamic therapy
A compact platform that keeps live-cell imaging and photodynamic therapy inside a single incubator could change how investigators track cellular response during repeated treatment cycles. The system combines inverted bright-field microscopy, automated X–Y scanning, and a uniform 630-nm illumination module, so the same culture does not need to be shuttled between separate imaging, incubation, and treatment setups. In practical terms, that reduces the mechanical drift, handling stress, and region-to-region inconsistency that often obscure the biology of time-dependent cancer experiments.
The device was built for continuity. It delivers a 1.5 mm² field of view at 2.2 μm resolution, while its mechanical and electronic design allows automated scanning and repeatable acquisition of predefined regions of interest. In a field where cellular behavior can change between one imaging pass and the next, the ability to return to the same coordinates matters because photodynamic injury unfolds over time rather than in a single instantaneous event.
Repeated observation of the same cells after 5-ALA exposure
To show the platform’s dual function, A375 melanoma cells exposed to 5-aminolevulinic acid at 10–500 µM underwent fractionated PDT and longitudinal imaging across 72 hours. This is the kind of experiment that is usually vulnerable to workflow noise: cells are moved, repositioned, and reacquired, and every transfer adds a chance for the imaging field to shift away from the original population. Here, treatment and observation were built into the same experimental sequence, which let the investigators monitor how the same cell group evolved after light activation.
A time- and dose-dependent decline in viability emerged in parallel with the imaging data. MTT assays confirmed that higher exposure and longer observation were associated with lower cell survival, a result that fits the biology of photodynamic injury, where photosensitizer activation generates reactive oxygen species and drives oxidative damage to cellular membranes, organelles, and death pathways. In melanoma cells, that mechanism is especially relevant because the therapeutic effect depends not only on light delivery but also on how uniformly the sensitizer is distributed and how completely the target field is illuminated.
The treatment effect was visible beyond the viability readout.
Morphologic drift, confluency loss, and the value of continuous tracking
Longitudinal image analysis captured treatment-associated changes in both cell confluency and individual-cell morphology over time. Those readouts are not cosmetic details; they are the earliest visible signs of stress, detachment, and progressive loss of adherence that often precede a collapse in bulk viability. When a photodynamic protocol is fractionated, the interval between exposures becomes biologically informative because surviving cells may flatten, retract, round up, or fragment in ways that reveal how close they are to irreversible injury.
Continuous monitoring also strengthens interpretation of dose-response relationships. In a conventional setup, a culture may be removed from the incubator for treatment, then transferred again for imaging, and each movement introduces optical and positional variability that can make true biologic change harder to separate from technical artifact. By anchoring the imaging path inside the incubator-compatible platform, the experimental setup preserves temporal continuity and gives investigators a cleaner view of the same populations across the entire treatment window.
Better region-of-interest preservation than manual transfer workflows
ROI overlap analysis showed substantially improved preservation of imaging regions compared with a conventional workflow that required repeated manual sample transfer. In cell biology, that is a deceptively important advance. If the field of view changes after each transfer, the analysis may drift from one cluster of cells to another, and the apparent treatment effect can be diluted by sampling error rather than biology. Stable ROI reacquisition means the measured changes in confluency and morphology are more likely to reflect the same cells under the same conditions.
For PDT studies, this kind of spatial fidelity is especially valuable because the treatment effect can be patchy when light distribution, photosensitizer uptake, or local cell density is uneven. A platform that preserves position while allowing repeated exposure and repeated imaging gives researchers a better chance of linking the optical dose to the eventual cellular outcome. It also opens the door to experiments that depend on prolonged observation, including fractionated protocols where the timing of each light dose influences the cumulative response.
Why incubator-compatible design matters for cancer phototherapy research
The technical logic behind the platform is straightforward. Photodynamic therapy depends on a three-part interaction among photosensitizer, oxygen, and light, and the cellular response evolves after irradiation rather than ending with it. If the culture can remain in a stable environment while being imaged and treated, then investigators can follow those delayed effects without interrupting the experiment or disturbing the same cell population. That matters for studies of apoptosis, membrane injury, proliferative arrest, and delayed recovery, all of which may emerge after the initial light exposure.
The 630-nm illumination module also fits the therapeutic logic of photodynamic therapy, since red light penetrates more deeply than shorter wavelengths in many experimental settings and is commonly used to activate porphyrin-based photosensitizers. The 5-ALA approach is biologically plausible because it serves as a precursor that can lead to intracellular accumulation of photosensitizing compounds, making cells more vulnerable to light-triggered oxidative injury. In a melanoma model, that setup provides a useful test bed for examining how optical delivery, sensitizer concentration, and time after treatment interact.
A short engineering paper can still carry real experimental consequences.
A platform for longitudinal cell studies beyond a single melanoma model
Although the demonstration focused on A375 melanoma cells, the platform was presented as an infrastructure for prolonged PDT protocols and other time-dependent cell-based studies. That broader use case is important. Many cancer and cell biology experiments require the same culture to be followed repeatedly under controlled conditions, yet standard workflows still separate imaging from intervention in ways that make continuous observation cumbersome. A single compact platform that combines imaging, scanning, and light delivery within the incubator reduces those barriers without changing the basic biology under study.
The study was supported by Iran University of Medical Sciences, and the authors reported no competing interests. The experimental demonstration is limited to a platform design and cell-based validation, so it does not address in vivo efficacy, tissue penetration, or clinical translation. The next questions are technical rather than rhetorical: how the system performs with other cell lines, how precisely it can quantify delayed post-PDT injury across larger datasets, and whether the same architecture can be adapted for other longitudinal assays that depend on stable ROI tracking and repeated observation over time.